Anton Y. Peleg
The Lancet · 2008–2022
A researcher in the Science corpus: 4 papers; trusts 0 researchers and is trusted by 5 researchers here, as inferred from the citation graph.
Whom Anton Y. Peleg trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Anton Y. Peleg overall
Papers from Anton Y. Peleg's perspective
Ordered by how strongly the researchers Anton Y. Peleg trusts endorse each paper. Same corpus, a different order for every researcher.
- The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. (FEMS Microbiology Letters)
- Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. (Clinical Infectious Diseases)
- Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. (Clinical Microbiology and Infection)
- Comparative Genomics of Multidrug Resistance in Acinetobacter baumannii (PLoS Genetics)
- Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. (Clinical Infectious Diseases)
- Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. (Clinical Infectious Diseases)
- Resistance-Nodulation-Cell Division-Type Efflux Pump Involved in Aminoglycoside Resistance in Acinetobacter baumannii Strain BM4454 (Antimicrobial Agents and Chemotherapy)
- Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. (Lancet. Infectious Diseases (Print))
- Global Challenge of Multidrug-Resistant Acinetobacter baumannii (Antimicrobial Agents and Chemotherapy)
- Trends in antimicrobial drug development: implications for the future. (Clinical Infectious Diseases)
Their papers
- Acinetobacter baumannii: Emergence of a Successful Pathogen (2008) — 3,455 citations
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis (2022) — 9,639 citations
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial (2018) — 675 citations
- Hospital-Acquired Infections Due to Gram-Negative Bacteria (2010) — 743 citations